Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions

Table 1 Hepatitis C virus resistance-associated substitutions to currently used direct-acting antiviral drugs

Drug family	Drug	Licensed for genotype	RAS
NS3 inhibitors	Glecaprevir (GLE)	1, 2, 3, 4, 5, 6	36M, 56H, 156G/V, 168A/K/L/R
	Grazoprevir (GZR)	1, 4	36A/L/M, 56H/F, 155G/K/L/Q/T/S, 156T/V, 168any
	Paritaprevir (PTV)	1, 4	36A/M, 43L, 155C/K/Q/H, 156T/V, 168any
	Voxilaprevir (VOX)	1, 2, 3, 4, 5, 6	36A/G/L/M, 41K/R/S/V, 43L/S7V, 54S, 55A/I, 56H/F, 80K/L, 122D/G/N, 155G/K/N/K/T/W, 156L/S/T/V, 168any
NS5A inhibitors	Daclatasvir (DCV)	1, 3, 4	24H, 28A/M/S/T, 30D/E/G/H/K/N/Q/R/S/T, 31I/F/M/V, 32L/del, 58A/D/N/S, 62L, 93C/H/N/R/S/W
	Elbasvir (EBR)	1, 3, 4	28G/T, 30G/H/K/R/V/Y, 31F/M/V, 58D, 93C/H/N
	Ledipasvir (LDV)	1, 3, 4, 5, 6	24N/G, 28A/M/T, 30E/G/H/K/N/R/S/T/Y, 31I/M/V, 32L/del, 38F, 58D, 92K/T, 93C/H/N/R/S/T/W
	Ombitasvir (OBV)	1, 4	28M/S/T/V, 30E/Q/R/Y, 31I/F/V, 32del, 58D, 92T, 93C/H/N/S
	Pibrentasvir (PIB)	1, 2, 3, 4, 5, 6	24R, 28G/K/S, 30K/R, 31I/M, 32del, 58C/D, 93H/N
	Velpatasvir (VEL	1, 2, 3, 4, 5, 6	28V, 30E/H/K, 31M/V, 32L, 93H/N/R/S/W
NS5B nucleoside analogs inhibitors	Dasabuvir (DSV)	1	316Y, 368T, 395G, 411S, 414T, 444K, 445F, 448C/H, 451S, 553T/V, 554S, 556G/N/R, 557R,558R, 559G/N, 561H, 565F
NS5B non-nucleoside analogs inhibitors	Sofosbuvir (SOF)	1, 2, 3, 4, 5, 6	159F, 282R/T, 289L, 320I/V, 321A

RAS: Resistance-associated substitutions.